Pendal Group’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
$491K Sell
10,612
-217
-2% -$9.4K ﹤0.01% 375
2022
Q3
$419K Sell
10,829
-653
-6% -$26.2K ﹤0.01% 361
2022
Q2
$428K Sell
11,482
-927
-7% -$37.7K ﹤0.01% 371
2022
Q1
$550K Sell
12,409
-48,640
-80% -$2.11M ﹤0.01% 394
2021
Q4
$2.59M Buy
61,049
+42,782
+234% +$1.8M 0.02% 212
2021
Q3
$792K Buy
18,267
+4,916
+37% +$217K 0.01% 352
2021
Q2
$571K Sell
13,351
-268
-2% -$11.3K 0.01% 401
2021
Q1
$526K Buy
13,619
+2,970
+28% +$112K 0.01% 402
2020
Q4
$383K Sell
10,649
-1,190
-10% -$42.9K ﹤0.01% 404
2020
Q3
$452K Sell
11,839
-7,224
-38% -$278K 0.01% 327
2020
Q2
$669K Buy
19,063
+6,625
+53% +$239K 0.01% 280
2020
Q1
$406K Buy
12,438
+1,463
+13% +$57.2K 0.01% 287
2019
Q4
$496K Sell
10,975
-89
-0.8% -$3.72K 0.01% 312
2019
Q3
$450K Sell
11,064
-881
-7% -$37.3K 0.01% 363
2019
Q2
$513K Buy
11,945
+940
+9% +$36.2K 0.01% 348
2019
Q1
$422K Buy
11,005
+3,693
+51% +$141K 0.01% 372
2018
Q4
$258K Buy
+7,312
New +$265K ﹤0.01% 371

Other funds holding BSX

Pendal Group's BSX Position: Q4 2022 in Review

Pendal Group reduced its Boston Scientific (BSX) stake by 2% in Q4 2022, selling an estimated $9.4K and leaving 10,612 shares worth $491K. The position accounts for ﹤0.01% of the portfolio, ranked #375.

Pendal Group first reported a position in BSX in Q4 2018 and has held it in 17 quarters since. The position peaked at $2.59M in Q4 2021. 928 funds tracked by Wall St. Rank hold BSX as of Q4 2022.

  • Pendal Group held 10,612 shares of Boston Scientific worth $491K as of Q4 2022.
  • Pendal Group sold 217 Boston Scientific shares in Q4 2022, an estimated $9.4K.
  • Boston Scientific made up ﹤0.01% of Pendal Group's portfolio in Q4 2022, its #375 holding.
  • Pendal Group first reported a position in Boston Scientific in Q4 2018 and has held it in 17 quarters since.
  • Pendal Group's Boston Scientific position peaked at $2.59M in Q4 2021.
  • 928 funds tracked by Wall St. Rank held Boston Scientific as of Q4 2022.

Based on Pendal Group's 13F filing for Q4 2022, filed 19 Jan 2023.